Summary The phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA) (10 nM) produced a marked reduction in the growth, measured by thymidine uptake, of MCF-7 cells in full growth medium, but had only a small effect on MDA-MB-231 and T47D cells. Bryostatin alone also inhibited growth but to a lesser extent than seen with TPA. The effect of TPA on (Sako et al., 1987) . Bryostatin also antagonises the induction of squamous differentiation in tracheobronchial epithelial cells by phorbol esters (Jetten et al., 1989 
The bryostatins are a group of macrocyclic lactones with antineoplastic activities isolated from marine bryozoans (Pettit et al., 1970) . The bryostatins have been shown to bind to and activate the calcium phospholipid dependent protein kinase C in a manner similar to phorbol esters, and to block phorbol ester binding (Smith et al., 1985; Berkow et al., 1985) . They may have a role to play in the treatment of tumours.
The effects of bryostatins have been studied in several cell systems in vitro, and in some systems they mimic the effects of phorbol ester while in others they appear to have antagonistic effects. The bryostatins, like phorbol esters, have been shown to act as mitogens in Swiss 3T3 cells (Smith et al., 1985) , induce superoxide production in human polymorphonuclear leucocytes (Berkow et al., 1985) , stimulate prolactin synthesis in GH4C5 rat pituitary cells (Ramsdell et al., 1986) , promote soft agar growth of JB6 mouse epidermal cells (Kraft et al., 1988) and inhibit cell coupling in mouse epidermal cells (Pasti et al., 1988) . In A549 human lung carcinoma cells (Dale & Gescher, 1989) bryostatin arrested cell growth in a similar manner to phorbol esters, but at higher concentrations abolished the inhibitory effect of TPA on growth.
In other systems, the bryostatins have been shown to inhibit phorbol ester induced responses or have an antagonist effect to phorbol esters. Unlike TPA, bryostatin is unable to induce differentiation in the human promyelocytic cell line HL60 (Kraft et al., 1986) although varying responses to bryostatin have been shown in four HL60 sublines (Kraft et al., 1989) and in a human colon cancer cell line (VOM), bryostatin counteracts the effect of TPA in inducing rapid terminal differentiation (McBain et al., 1988) . Bryostatin blocked phorbol ester induced arachidonic acid metabolite release in mouse fibroblast cells (Dell'Aquila et al., 1988) and had a differing effect on EGF binding in these cells. The inhibition of epidermal growth factor (EGF) binding to mouse epidermal cells with phorbol esters was abolished by the addition of bryostatin, although in some reactions in this cell line, bryostatin mimicked the effect of phorbol esters (Sako et al., 1987) . Bryostatin also antagonises the induction of squamous differentiation in tracheobronchial epithelial cells by phorbol esters (Jetten et al., 1989 
Materials and methods
Routine cell culture All cell lines were maintained in Eagle MEM containing 10% foetal calf serum, 20 mM glutamine, 2 g -' sodium bicar-bonate, 1 mM sodium pyruvate, 100 U ml-' penicillin and 0.1 mg ml1 streptomycin. Routine cultures were grown in 25 cm2 tissue culture flasks, and subcultured weekly using 0.25% Trypsin + 0.2% EDTA in DulA. Cultures were checked at monthly intervals to ensure they were free from mycoplasma contamination. Cultures were maintained at 37°C in a humidified incubator gassed with 95% air, 5% CO2.
Oestradiol stimulation
In experiments where oestradiol stimulation was studied, cells were seeded into 96 well plates in phenol red free medium (Flow Autopow) containing 10% dextran coated charcoal treated foetal calf serum. Cells were maintained in this medium for 4 days before test medium was added.
3H-thymidine uptake Cells were seeded into 96 well plates using 0.2 ml medium per well. After 48 h the medium was removed and replaced with test medium for a further 48 h. Where mixtures of TPA and bryostatin were used, the medium containing the required concentrations was prepared before addition of the medium to the cells. The test medium was removed, cells washed with PBS and 3H-thymidine (100 nM) in serum-free medium added for 2 h. The cells were washed after removal of the radioactive medium, solubilised in 0.5 M sodium hydroxide and the DNA collected onto filters by means of a Titretek cell harvester. The filters were counted for radioactivity using an LKB liquid scintillation counter. Control incubations were used in each assay and results expressed as thymidine uptake as a percentage of controls. Six replica determinations were carried out for each point and the mean and associated SEM plotted. In preliminary experiments we had established that uptake of 3H-thymidine correlates well with cell number. mRNA levels of oestrogen-responsive genes MCF-7 cells were depleted of oestrogens using the method of May and Westley (1988) , by using phenol red free medium containing 10% FBS treated with dextran coated charcoal, for 6 days. Large petri dishes were used for the cells, and after 24 h of treatment with oestradiol alone or in combination with TPA or bryostatin, RNA was prepared by the RNAzol method (Chomczynski & Sacchi, 1987) . Northern blot hybridisation was used to measure the mRNA levels for the oestrogen responsive genes pNR100 (Cathepsin-D) and pNR2 (pS2) (May & Westley, 1986) . The pNR2 and pNR100 probes were labelled by the random primer extension method (Feinberg & Vogelstein, 1983) . Standard Northern blot hybridisation procedures using the glyoxal method were employed, as described elsewhere (Mason & Williams, 1985) . For all Northern blots gels were stained with ethidium bromide prior to transfer to nylon membranes in order to check equal loading. Subsequent reprobing of filters with an 18S ribosomal RNA probe was used to verify loading and transfer.
TGF-PI expression
Northern blot hybridisation was also used to measure TGF-P1 mRNA levels in cells treated with combinations of oestradiol, TPA and bryostatin, under conditions described for oestrogen genes above. The hybridisation probe used was an insert preparation from a TGF-P1 cDNA clone supplied by Dr Rik Derynck, Genentech (Derynck et al., 1985) .
Results
Effects of TPA and bryostatin on 3H-thymidine uptake The effects of TPA, bryostatin and equimolar mixtures of TPA and bryostatin differed in the three cell lines tested, as shown (Figure la,b,c) . MDA cells showed a 30% decrease in thymidine uptake with both TPA and bryostatin and equimolar concentrations of both. No reduction in 3H-thymidine uptake was found in the T47D cells after 48 h with either of these agents, and when this test incubation was extended to 5 days no effect was again found. Bryostatin had a significant growth inhibitory effect on MCF-7 cells, with uptake of 3H-thymidine reduced to 70% of control with 100 nM bryostatin. However, a more pronounced reduction to less than 10% of control was seen with 10 nM TPA. This reduction of thymidine uptake with TPA was partially reversed by the use of equimolar concentrations of bryostatin. With 1O nM TPA growth inhibition was reduced to 6.3 ± 0.7% (n = 6) of control, whereas with 10 nM TPA plus 10 nM bryostatin the growth inhibition was reduced to only 30 ± 4% (n = 6) of control. This difference was statistically significant (P <0.05).
The antagonistic effect of byrostatin on the response of MCF-7 cells to TPA was further studied by increasing the concentration of byrostatin with a fixed concentration of 50 nM TPA using 48 h incubations ( Figure Id) . With increasing concentrations of bryostatin, the 3H-thymidine uptake was increased but the effect of 50 nM TPA could not be completely overcome even with 1 gM bryostatin.
The growth inhibitory effect of TPA on MCF-7 cells remained at the same level with increasing concentrations from l0nM to 1 gM with 48 h incubation. The time course of the effect of 50 nM TPA on MCF-7 cells was investigated by varying the time of treatment of cells with TPA from 48 h to 2 h before labelled thymidine was added. The results are shown in Figure 2 . The thymidine uptake was reduced by 50% with 4 h incubation with TPA, and maximum reduction to 7 % was achieved after 18 h treatment.
Since incubation with bryostatin partially reversed the growth inhibitory effect of TPA on MCF-7 cells, the effect of TPA treatment time before addition of bryostatin was investigated. Cells were treated with 50 nM TPA for 2 to 6 h, after which time the cells were washed before addition of control medium or medium containing bryostatin for the remainder of the 48 h incubation. The results are shown in Figure 3 . After 6 h incubation with TPA, bryostatin was still able to partially reverse the effect of the TPA on 3H-thymidine uptake. Figure 4 . In the T47D cell line, oestradiol greatly increased the thymidine uptake of the cells whereas in the MCF-7 cells 0.1 nM oestradiol only doubled the thymidine uptake compared to the control. In depleted medium and the absence of oestradiol both TPA and bryostatin stimulated the uptake of 3H-thymidine into T47D cells, and had no influence on the growth stimulatory effect of oestradiol on these cells. In contrast, in the MCF-7 cell line, in addition to having growth inhibitory effects alone, TPA prevented the growth stimulation by oestradiol. The oestradiol stimulation of growth was not influenced by the presence of bryostatin alone but bryostatin partially antagonised the effects of TPA on oestradiol stimulated growth. In the presence of TPA 3Hthymidine uptake in MCF-7 cells remained at less than 10% of control when oestradiol was added. However, when bryostatin was included with TPA the 3H-thymidine uptake was only reduced to 80% of control.
The effects of TPA and bryostatin on the transcription of oestrogen responsive genes Cells depleted of oestradiol were stimulated for 24 h with oestradiol, TPA or bryostatin or mixtures of oestradiol and TPA or bryostatin. The effect on mRNA levels of the oestrogen-responsive genes pNR2 and pNRIOO was investigated ( Figures 5 and 6 ). In MCF-7 cells both oestradiol and TPA increased pNR2 mRNA. Bryostatin alone had no effect. The growth inhibitory effect of TPA is thought to be mediated by binding to protein kinase C. However, the effect of TPA varied in the three cell lines studied in a manner which did not correlate with either the oestrogen receptor status or the reported protein kinase C concentration in these cells (Borner et al., 1988; Fabbro et al., 1986) , where ER negative cells displayed higher amounts of protein kinase C compared to ER positive cell lines: MDA> MCF-7> T47D. The relatively low amount of protein kinase C in T47D cells may explain the lack of any effect of TPA or bryostatin on growth or pNRIOO mRNA in these cells compared with MCF-7 cells. A rapid decrease in cytosolic protein kinase C after TPA treatment of MCF-7 cells has been described (Issandou et al., 1986) and subsequently it was shown that only 10% of initial protein kinase C activity remains in MCF-7 cells after 48 h of TPA treatment (Issandou et al., 1988) . The rapid translocation of protein kinase C activity from the cytosolic to particulate fractions of the cell and the rapid decrease in phorbol ester binding capacity at the membrane level suggest a down-regulation of protein kinase C in response to TPA treatment (Darbon et al., 1987) . However the role of protein kinase C downregulation in the growth inhibitory effect of TPA is not clear. Figure 6 Northern blot hybridisation of T47D cell RNA with pNR2, pNR100 and 18S rRNA. Treatment of cells as Figure 6 . M: RNA sample from MCF-7 cells.
18S-
The combination of oestradiol with bryostatin increased pNR2 mRNA but not to a greater extent than seen with oestradiol alone. However, the combined effect of oestradiol and TPA had a marked synergistic effect in increasing the mRNA level of pNR2 ( Figure 5 ). With pNRIOO, an increased signal was obtained with TPA, oestradiol and bryostatin. A synergistic effect was obtained with the combination of TPA and oestradiol. Also, in contrast to the lack of effect on pNR2, bryostatin had a synergistic effect on pNRIOO mRNA when combined with oestradiol ( Figure 5 ). With T47D cells, no pNR2 transcripts were detected, and an increase in pNRIOO was only found with oestradiol ( Figure 6 ). Neither TPA nor bryostatin significantly altered pNRIOO mRNA levels whether present alone or combined with oestradiol. The interaction between oestradiol and TPA was studied in the hormone-sensitive cell lines. In the T47D cell line, the oestrogen-induced growth response was unaffected by both TPA and bryostatin. In the MCF-7 cell line, the oestrogen response was blocked by TPA. These results are in agreement with those of Valette et al. (1987) , who has shown that TPA blocks the increase in S phase cells induced by oestradiol. To investigate whether TPA has a direct effect on the action of oestradiol in the MCF-7 cells, we studied the effect of TPA and oestradiol on mRNA levels for the oestrogen-inducible genes pNR2(pS2) and pNR100(Cathepsin D). Our results show that the inhibitory effects of TPA on growth stimulation by oestradiol was not attributable to any general inhibtion of the transcription of oestrogen responsive genes. On the contrary, treatment of MCF-7 cells with TPA or bryostatin lead to marked increases in the mRNA levels of the two oestrogen responsive genes examined, beyond that achieved with either agent alone.
It has recently been shown that, in addition to stimulation by oestradiol, pNR2(pS2) and pNR100(Cathepsin D) are induced in MCF-7 cells by other growth factors such as IGF1, EGF and FGF (Cavailles et al., 1989 ). An increase in pNR2 but not pNR100 mRNA in response to TPA treatment was also reported. In our experiments mRNA levels for both of these oestrogen-responsive genes were increased by TPA treatment. The 5' regulatory sequence of the pS2 gene has been described (Jeltsch et al., 1987) . Although the authors did not address themselves to this question, inspection of the sequence reveals the presence of two putative TPA responsive elements, TCTCTCAC at -348 and TGTCTCAG at -100 relative to the transcriptional start site, which match the defined consensus sequence (Angel et al., 1987) . The presence of these elements is consistent with the observed effect of TPA on pNR2 mRNA levels. Further studies are required to establish if these putative TPA response elements are functional and whether direct transcriptional regulation of the pNR2 gene is involved. At present there is no information available on the regulatory sequences of the pNR100 gene.
The synergistic effect of combined TPA and oestradiol on transcript levels of oestrogen-responsive genes has not been previously reported. Whether the mechanism for this operates at the transcriptional level or whether de novo protein synthesis is required remains to be established. However, such an effect could conceivably result from an increase in protein kinase C levels in response to oestradiol or an increase in oestradiol receptors in response to TPA. The latter possibility appears to be ruled out by Lee et al. (1989 ) who reported an inhibitory effect of TPA on oestrogen receptor levels in MCF-7 cells. This reduction in oestradiol receptor levels may contribute to an explanation of the ability of TPA to block the stimulation of growth by oestradiol in MCF-7 cells.
The inhibitory action of TPA on MCF-7 cells is well documented and it has been suggested that part of the action of TPA may be attributed to its ability to activate protein kinase C, which leads to phosphorylation of the EGFreceptor and a resultant acute decrease in binding affinity (Lee et al., 1989) . However, these same changes in EGF-receptor function are also observed in systems for which TPA has a growth stimulatory effect, such as Swiss 3T3 cells (Brooks & Brooks, 1990) . Thus the role of the EGF-receptor in growth inhibition of MCF-7 cells by TPA is equivocal.
An additional possibility examined to explain the growth inhibition of MCF-7 cells by TPA and bryostatin, was that these agents might be stimulating the expression of TGF-il, acting as an autocrine growth inhibitory factor. TGF-P1I peptide has been shown to be produced by MCF-7 cells and to be hormonally regulated in this cell line (Knabbe et al., 1987) . TGF-P1 has been reported to be reduced in MCF-7 cells treated with oestradiol (Dickson et al., 1986) and we have confirmed this observation in our study. In addition, we found treatment with TPA increased TGF-P1 mRNA, consistent with the autocrine growth inhibition hypothesis. The presence of functional TPA response elements in both the 5' and, more unusually, the 3' regions of the human TGF-P1 gene is consistent with these observations (Kim et al., 1989; Scotto et al., 1990) . Furthermore, the combined effect of oestradiol and TPA produced a marked increase in TGF-P11 mRNA, above that seen with TPA alone, even though oestradiol alone led to a reduction of TGF-P1 mRNA levels. Bryostatin did not have a similar effect on TGF-P1 expression, producing only a small increase in TGF-,B mRNA with no further effect when combined with oestradiol. Thus TPA and bryostatin appear to have overlapping but also different effects on these and other cells.
Although we observed that treatment of MCF-7 cells with TPA and combinations of TPA and oestradiol increased the level of TGF-P1 mRNA, the ability of TGF-PI to inhibit MCF-7 cell growth is not clear, since conflicting reports appear in the literature. Zugmaier et al. (1989) have compared the effect of TGF-P on both early (<100) and late passage (>500) MCF-7 cells and found growth inhibition only in the former, attributing the lack of growth inhibition in late passage cells to loss of TGF-P receptors. In our studies late passage (> 300) cells were used and we were also unable to find any evidence of growth inhibition with exogenous TGF-P (data not shown). However, it is still not possible for us to reject the autocrine growth inhibition loop hypothesis, since it may be that the effect of TPA is 2-fold, with not only an increase in TGF-P expression but also the induction of a necessary upregulation of TGF-P receptor expression. Without the latter the effect of exogenous TGF-P may not be manifested. Only low numbers of TGF-P receptors have been found in MCF-7 cells (Arteaga et al., 1988; Guerrin et al., 1990) . TPA may have the effect of increasing TGF-P receptors to the level at which the cells become responsive to the growth inhibitory effect of the concort,itantly elevated TGF-P expression. Such a 2-fold autocrine inhibitory mechanism has been implicated in the TPA-induced growth inhibition of other cell types (Sing et al., 1990; Takaishi et al., 1990) . The possibility of a similar mechanism operating in MCF-7 and other tumour cells which are growth inhibited by TPA and other protein kinase C activators merits further investigation.
Bryostatin is due to enter phase I clinical trials. The ability of bryostatin to both mimic and antagonise the effects of TPA suggests that it has both similar and different interactions with protein kinase C compared with TPA. Our results indicate that the response of breast tumours to bryostatin will vary and it seems likely this will depend on the growth signal transduction pathway status of individual tumours. Further studies are required to establish tests which will identify tumours likely to respond to agents which interact with protein kinase C.
